Levofloxacin Use in Patients with Suspected Tuberculosis in a Community Hospital, Thailand: A Pilot Study. (3rd June 2022)

• Record Type: Journal Article
• Authors: Khongyot, Thanawat; Laopaiboonkun, Sawitree; Kawpradid, Throngpon; Jitkamrop, Kannuwat; Chanphakphoom, Tawee; Uitrakul, Suriyon
• Other Names: Suksaeree Jirapornchai Academic Editor.
• Is Part Of: Advances in pharmacological and pharmaceutical sciences. Volume 2022(2022)
• Publication Date: 2022-06-03
• Subjects: Pharmacology -- Periodicals; 615.1
• DOI: 10.1155/2022/5647071
• Languages: English
• ISSNs: 2633-4682

Abstract

Abstract : Background . Levofloxacin is one of the broad-spectrum antibiotics that is indicated for the second-line treatment of tuberculosis (TB). However, using levofloxacin as an empirical therapy for patients without confirmation of TB could still be observed. This descriptive retrospective study, therefore, aimed to investigate the number of levofloxacin use in patients suspected TB in a community hospital in Thailand. Methods . Patient medical charts of all patients who were admitted to a community hospital in Nakhon Si Thammarat, Thailand, from 2016 to 2017, were reviewed. Patients who were suspected TB and received any levofloxacin-containing regimens were included. Data on patient characteristics and the received regimens were descriptively analyzed and reported as percentage and frequency. Results . There were a total of 21 patients who received levofloxacin in the hospital. Six of them (28.57%) had the diagnosis of hepatitis. The most prescribed regimen as empirical therapy was levofloxacin, ethambutol, and amikacin (66.67%). After the confirmation of TB using acid-fast bacilli (AFB) test, ten patients (47.62%) still received levofloxacin-containing regimens. Conclusion . The results from this study indicated high usage of levofloxacin despite no evidence of drug-resistant TB or negative AFB results in a community hospital in Thailand. The results from this study will be further used for the investigation of the prevalence of antibiotic resistance and clinical outcomes of using second-line regimens for TB treatment.